Company: VRCA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001660334-25-000006
Chunk: 16

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
)Net cash used in investing activities— (27)Cash flows from financing activitiesProceeds from exercise of stock options— 154 Payment of debt amendment fees— (1,139)Repayment of debt(11,919)— Repayment of finance lease(277)(550)Payment of equity issuance costs— (163)Net cash used in financing activities(12,196)(1,698)Net decrease in cash and cash equivalents(25,232)(46,588)Cash and cash equivalents at the beginning of the period46,329 69,547 Cash and cash equivalents at the end of the period$21,097 $22,959 

5

Table of ContentsVERRICA PHARMACEUTICALS INC.STATEMENTS OF CASH FLOWS(in thousands)(Unaudited)

For the Nine Months Ended September 30,20252024Supplemental disclosuresCash paid for interest$4,353 $5,492 Supplemental disclosure of noncash investing and financing activities:Recognition of R&D funding liability and deferred R&D services$4,313 $— Finance lease liability extinguished as a result of lease termination$50 $— Right-of-use asset obtained in exchange for lease obligation$141 $1,976 

The accompanying notes are an integral part of these financial statements.

6

VERRICA PHARMACEUTICALS INC.

Notes to Financial Statements

(Unaudited)

Note 1—Organization and Description of Business Operations

Verrica Pharmaceuticals Inc. (the "Company") was formed on July 3, 2013 and is incorporated in the State of Delaware. The Company is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. On July 21, 2023, the U.S. Food and Drug Administration ("FDA") approved YCANTH (VP-102) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older.Reverse Stock SplitAt the close of trading on July 24, 2025, the Company effected a reverse stock split at a ratio of 1-for-10 shares of its common stock. As a result, every ten shares of the Company’s issued and outstanding common stock were automatically combined into one share. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage ownership interest in the Company. No fractional shares were issued as a result of the reverse stock split